A survey on staging and treatment in uterine cervical carcinoma in the Radiotherapy Cooperative Group of the European Organization for Research and Treatment of Cancer

Radiotherapy and Oncology

Volumn 54, Issue 3, 2000, Pages 221-228

  Coucke, Philippe A ^a   Maingon, Philippe ^b   Ciernik, Ilja F ^a   Phuoc Do, Huu ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Cervix cancer; Chemo radiotherapy; Pretreatment evaluation; Surgery

Indexed keywords

CISPLATIN; GEMCITABINE; HYDROXYUREA; IDOXURIDINE; IRINOTECAN; MISONIDAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; RADIATION INJURY; TECHNIQUE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VARIANCE;

BRACHYTHERAPY; DATA COLLECTION; EUROPE; FEMALE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; UTERINE CERVICAL NEOPLASMS;

EID: 0034163466     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00146-8     Document Type: Article

References (41)

1. Barillot I., Horiot J.-C., Pigneux J., et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;969-978.
2. Bauer M., Leibel S., Wasserman T., et al. Effect of misonidazole dose on survival in patients with stage IIIB-IVA squamous cell carcinoma of the uterine cervix. Int J. Radiat. Oncol. Biol. Phys. 12:1986;1101-1103.
3. Bonin S., Lanciano R., Corn B.W., Hogan W.M., Hartz W.H., Hanks G. Bony landmarks are not an adequate substitute for lymphangiography in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;167-172.
4. Britten R.A., Evans A.J., Allalunis-Turner M.J., Pearcey R.G. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;367-374.
5. Chassagne D., Sismondi P., Horiot J-C., et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother. Oncol. 26:1993;195-202.
6. Delaloye J-F., Coucke P.A., Pampallona S., De Grandi P. Effect of total treatment time on event-free survival in carcinoma of the cervix. Gynecol. Oncol. 60:1996;42-48.
7. Dische S. On behalf of the MRC Working Party on advanced carcinoma of the cervix: a trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother. Oncol. 26:1993;93-103.
8. Eifel P., Thames H.D. Has the influence of treatment duration on local control of carcinoma of the cervix been defined? Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1527-1529.
9. Fine B.A., Hempling R.E., Piver M.S., Baker T.R., McAuley M., Driscoll D. Severe radiation morbidity in carcinoma of the cervix. Impact of pretherapy surgical staging and previous surgery. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;717-723.
10. Eifel P.J., Morris M. Irradiation alone or combined with surgery in carcinoma of the cervix. When will we know the answer? Int. J. Radiat. Oncol. Biol. Phys. 31:(4):1995;1007-1008.
11. Fyles A., Keane T.J., Barton M., Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother. Oncol. 25:1992;273-279.
12. Girinsky T., Rey A., Roche B., et al. Overall treatment time in advanced cervical carcinoma: a critical parameter in treatment outcome. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;1051-1056.
13. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91.
14. Haie C., Pejovic M.H., Gerbaulet A., et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol. 11:1988;101-112.
15. Heller P.B., Malfetano J.H., Bundy B.N., Barnhill D.R., Okagaki T. Clinical-pathological study of stage IIB, III and IVa carcinoma of the cervix: extended diagnostic evaluation for para-aortic node metastases - a Gynecologic Oncologic Group Study. Gynecol. Oncol. 38:1990;425-430.
16. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:1993;45-50.
17. Höckel M., Schlenger K.H., Aral B., Mitze M., Schäffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
18. Kapp D.S., Giaccia A.J. New directions for radiation biology research in cancer of the uterine cervix. J. Natl. Canc. Inst. 21:1996;131-139.
19. Kim C.Y., Tsai M.H., Osmanian C., et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 57:1997;4200-4204.
20. Kim R.Y., McGinnis S., Spencer S.A., Meredith R.F., Jenelle R.L.S., Salter M.M. Conventional four field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss. Radiother. Oncol. 30:1994;140-145.
21. Lanciano R.M., Pajak T.F., Martz K., Hanks G.E. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;391-397.
22. Landoni F., Maneo A., Colombo A., et al. Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 350:1997;535-540.
23. Lambin P., Gerbaulet A., Kramar A., et al. Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at 2 years. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;405-412.
24. Leborgne F., Leborgne J.H., Doldan R., et al. Induction chemotherapy and radiotherapy of advanced cancer of the cervix. A pilot study and phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;343-350.
25. Montana G.S., Hanlon A.L., Brickner T.J., et al. Carcinoma of the cervix. Patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1481-1486.
26. Morris M., Eifel P.J., Lu J., et al. Pelvic irradiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340:1999;1137-1143.
27. Perez C.A. Changing patterns of care in carcinoma of the uterine cervix. Need for cost-benefit studies. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1535-1537.
28. Perez C.A., Grigsby P.W., Castro-Vita H., Lockett M.A. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1275-1288.
29. Petereit D.G., Sarkaria J.N., Chappell R., et al. The adverse effect of treatment prolongation in cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 32:(5):1995;1301-1307.
30. Potish R.A., Twiggs L.B. On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;975-979.
31. Potish R.A. Surgical staging, extended field radiation, and enteric morbidity in the treatment of cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 31:(4):1995;1009-1010.
32. Rose P.G., Bundy N.B., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally-advanced cervical cancer. N. Engl. J. Med. 340:1999;1144-1153.
33. Rotman M., Pajak T.F., Choi K., et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIb and bulky Ib and IIa cervical carcinomas. Ten-year treatment results of RTOG 79-20. J. Am. Med. Assoc. 274:1995;387-393.
34. Russell A.H., Shingleton H.M., Jones W.B., et al. Trends in the use of radiation and chemotherapy in the initial management of patients with carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;605-613.
35. Sarkaria J.N., Petereit D., Stitt J., et al. A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;75-82.
36. Shueng P-W., Hsu W-L., Jen Y-M., Wu C-J., Liu H-S. Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally-advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;889-896.
37. Souhami L., Gil R.A., Allan S.E., et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIb carcinoma of the cervix. J. Clin. Oncol. 9:1991;970-977.
38. Stehman F.B., Bundy B.N., Thomas G., et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J. Clin. Oncol. 11:1993;1523-1528.
39. Teshima T., Inoue T., Ikeda H., et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer. 72:1993;2409-2413.
40. pot in cancer of the uterine cervix. Correlation between two laboratories and preliminary clinical results. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1319-1329.
41. Vigliotti A.P., Wen B-C., Hussey D.H., et al. Extended field irradiation for carcinoma of the uterine cervix with positive peri-aortic nodes. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;501-509.